Laurus Labs Q3 FY26: Revenue up 26%, PAT jumps 178% YoY

Revenue Growth 20pctPat Growth 25pctResults View source PDF Explain this filing

LAURUSLABS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+1.6%Reaction day

₹1014.00

prior close

₹1025.90

announcement price

In-mkt

timing

Nifty Midcap 150market · index membership as recorded later (tracked since Jun 2026)-1.7%+3.3% vs market

Pharmaceuticals peers, median of 155sector-1.5%+3.1% vs sector

On the reaction day the stock moved 3.3 pts more than Nifty Midcap 150 and 3.1 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+1.2

10m

-0.4

15m

-1.2

30m

-0.8

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+1.6-1.7+3.3-1.5+3.1

Next day

-1.5-1.2-0.3-2.1+0.6

-1.2+0.4-1.6-0.9-0.3

-4.3+0.5-4.8-1.3-3.0

-4.7+0.5-5.3-1.1-3.7

-5.6-0.6-5.0-1.3-4.3

-3.7+2.9-6.7+1.5-5.3

15d

-0.3+2.8-3.1+0.2-0.5

+0.1+2.4-2.3+0.3-0.2

-5.2-9.0+3.9-9.9+4.7

+11.4+3.4+8.1+2.5+8.9

UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 155Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Laurus Labs posted Q3 consolidated revenue of Rs 1,778 crores, up 26% YoY. Net profit surged 178% YoY to Rs 252 crores. Nine-month PAT rose to Rs 608 crores from Rs 126 crores. Standalone PAT was Rs 175 crores versus Rs 57 crores. Auditors Deloitte Haskins and Sells issued an unmodified review report. Demerger scheme with Laurus Synthesis pending NCLT approval.

Likely market impact

Strong top-line and bottom-line growth, clean auditor review. Restructuring scheme with subsidiary is a near-term monitorable.